The identification of IDH1 mutations has also led to the development of targeted therapies. IDH1 inhibitors are designed to specifically inhibit the mutant form of the enzyme, thereby reducing the levels of the oncometabolite 2-HG. These inhibitors have shown promise in clinical trials, particularly for patients with IDH1-mutant cancers, by potentially halting tumor growth and improving survival rates.
